DAE HWA Pharmaceutical Co., Ltd. (KOSDAQ:067080)
South Korea flag South Korea · Delayed Price · Currency is KRW
10,960
+360 (3.40%)
At close: Sep 4, 2026

DAE HWA Pharmaceutical Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
148,754143,060149,409141,359131,912117,159
Other Revenue
0---0--
148,754143,060149,409141,359131,912117,159
Revenue Growth
0.14%-4.25%5.70%7.16%12.59%7.14%
Cost of Revenue
97,27596,12197,19796,69886,29873,907
Gross Profit
51,47946,93952,21244,66145,61443,252
Selling, General & Admin
39,12237,20336,67734,30932,49631,345
Research & Development
4,9345,1857,2415,9845,3746,641
Amortization of Goodwill & Intangibles
928.53901.53979.81,0801,0501,017
Other Operating Expenses
374.75354.85348.08347.44352.59308.25
Operating Expenses
45,94843,77745,50042,69939,76739,968
Operating Income
5,5313,1626,7121,9625,8473,284
Interest Expense
-4,876-4,794-5,458-4,674-2,365-1,519
Interest & Investment Income
185.32125.9630.35341.26348.19427.24
Earnings From Equity Investments
------212.81
Currency Exchange Gain (Loss)
103.28-68.05-158.744.83-15.35104.33
Other Non Operating Income (Expenses)
1,6921,6231,0911,6612,2534,019
EBT Excluding Unusual Items
2,63549.942,217-664.36,0676,103
Impairment of Goodwill
------1,431
Gain (Loss) on Sale of Investments
576.02181.57-366.55381.4-766.9362.47
Gain (Loss) on Sale of Assets
----18.07-1.21-1.07
Asset Writedown
4,5474,547-337-155-2,873-1,182
Other Unusual Items
----0.05673.21
Pretax Income
7,7584,7791,513-455.972,4264,525
Income Tax Expense
2,8962,449683.3358.351,2052,562
Earnings From Continuing Operations
4,8622,330829.84-514.321,2211,962
Minority Interest in Earnings
-428.17-676.46-298.42-632.48-105.5254.96
Net Income
4,4341,654531.42-1,1471,1162,217
Net Income to Common
4,4341,654531.42-1,1471,1162,217
Net Income Growth
579.76%211.15%---49.69%-
Shares Outstanding (Basic)
181818181817
Shares Outstanding (Diluted)
181818181817
Shares Change
2.40%-1.04%1.13%-0.33%0.87%
EPS (Basic)
247.9694.3330.00-65.4763.69127.00
EPS (Diluted)
247.9694.3330.00-65.4763.69127.00
EPS Growth
563.81%214.43%---49.85%-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-2,5012,591875.3-9,122-19,497701.81
Free Cash Flow Per Share
-139.86147.8349.41-520.75-1113.0840.20
Dividend Per Share
---150.000150.000-
Dividend Growth
---0%--
Gross Margin
34.61%32.81%34.95%31.59%34.58%36.92%
Operating Margin
3.72%2.21%4.49%1.39%4.43%2.80%
Profit Margin
2.98%1.16%0.36%-0.81%0.85%1.89%
Free Cash Flow Margin
-1.68%1.81%0.59%-6.45%-14.78%0.60%
EBITDA
11,7479,42913,1177,83310,3888,102
EBITDA Margin
7.90%6.59%8.78%5.54%7.88%6.92%
D&A For EBITDA
6,2166,2676,4055,8714,5414,818
EBIT
5,5313,1626,7121,9625,8473,284
EBIT Margin
3.72%2.21%4.49%1.39%4.43%2.80%
Effective Tax Rate
37.33%51.24%45.16%-49.67%56.63%
Advertising Expenses
-1,5541,6963,1273,2563,598